As of Friday close, Edwards Lifesciences Corporation’s (NYSE:EW) stock was up $4.11, moving up 4.40 percent to $97.55. The average number of shares traded per day over the past five days has been 3,367,380 shares. 1 time new highs have been achieved over the past 5 days, with a -$2.97 fall in that time frame. In the last twenty days, the average volume was 3,376,070, while in the previous 50 days, it was 2,842,274.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, EW stock retreated -19.98%. Shares of the company fell to $91.52 on 05/12/22, the lowest level in the past month. A 52-week high of $131.73 was reached on 04/21/22 after having rallying from a 52-week low of $87.36. Since the beginning of this year, EW’s stock price has dropped by -24.70% or -$32.00, and marked a new high 3 times. However, the stock has declined by -25.95% since its 52-week high.
Edwards Lifesciences Corporation (EW) last reported insider trading activity 4 days ago on May 10. Wood Larry L, the CVP, TAVR of the company, disposed of 7,242 shares for $96.13 on May 10. It resulted in a $696,181 divestment by the insider. MUSSALLEM MICHAEL A sold 32,550 shares at an average price of $94.82 on May 10. The insider now owns 157,353 shares following the transaction. On May 09, CVP, EMEA, Canada, Latin Amer Lemercier Jean-Luc M sold 11,560 shares at $98.24 apiece. The transaction was valued at $1,135,709.
Right now, Edwards Lifesciences Corporation (EW) has a P/E ratio of about 39.98. The stock’s beta is 1.16. Besides these, the trailing price-to-sales (P/S) ratio of 11.64, the price-to-book (PB) ratio of 10.38, and the price-to-cash flow ratio of 43.54 may also be considered.
In the three months ended March 30, Edwards Lifesciences Corporation’s quick ratio stood at 2.60, while its current ratio was 3.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.10, and the total debt-to-equity ratio was 0.10. On the profitability front, the trailing twelve-month gross margin is 76.60% percent. In the year ended March 30, operating margins totaled 32.60%. Based on annual data, EW earned $3.98 billion in gross profit and brought in $5.23 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 23.20%. Return on equity (ROE) for the past 12 months was 27.50%.
In Edwards Lifesciences Corporation’s quarter-end financial report for March 30, it reported total debt of $595.9 million against cash and short-term investments of $465.0 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. EW’s revenue rose 9.29% to $1.33 billion during the quarter, while net income inched up to $1.34 billion. While analysts expected Edwards Lifesciences Corporation to report $0.57 quarterly earnings, the actual figure was $0.6 per share, beating the consensus estimate by 5.30%. During the quarter, the company generated $473.5 million in EBITDA. The liabilities of Edwards Lifesciences Corporation were 2.58 billion at the end of its most recent quarter ended March 30, and its total debt was $688.2 million. The value of shareholders’ equity is $621.75 million.
This quick technical analysis looks at Edwards Lifesciences Corporation’s (EW) price momentum. With a historical volatility rate of 50.18%, the RSI 9-day stood at 34.83% on 13 May.
With respect to its five-day moving average, the current Edwards Lifesciences Corporation price is down by -2.95% percent or -$2.97. At present, EW shares trade -18.72% below its 20-day simple moving average and -18.73% percent below its 100-day simple moving average. However, the stock is currently trading approximately -12.89% below its SMA50 and -12.61% below its SMA200.
Stochastic coefficient K was 9.85% and Stochastic coefficient D was 5.81%, while ATR was 4.45. Given the Stochastic reading of 21.25% for the 14-day period, the RSI (14) reading has been calculated as 35.58%. As of today, the MACD Oscillator reading stands at -4.38, while the 14-day reading stands at -8.01.
Truist launched its rating on Edwards Lifesciences Corporation (NYSE: EW) to a Buy in a note to investors on April 13, 2022. Edwards Lifesciences Corporation (EW) has been rated Overweight by analysts. According to 0 brokerage firms , EW is a sell, and 7 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Edwards Lifesciences Corporation stock as buy, with 16 recommending it as overweight.
With a median target price of $133.50, the current consensus forecast for the stock is $105.00 – $140.00. Based on these forecasts, analysts predict Edwards Lifesciences Corporation (EW) will achieve an average price target of $129.15.